Terns Pharmaceuticals Stock Today
| TERN Stock | USD 6.34 0.46 7.82% |
Performance0 of 100
| Odds Of DistressOver 51
|
Terns Pharmaceuticals is selling at 6.34 as of the 28th of November 2024; that is 7.82 percent increase since the beginning of the trading day. The stock's open price was 5.88. Terns Pharmaceuticals has 51 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Terns Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of February 2021 | Category Healthcare | Classification Health Care |
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. The company has 84.94 M outstanding shares of which 4.54 M shares are at this time shorted by private and institutional investors with about 3.16 trading days to cover. More on Terns Pharmaceuticals
Moving together with Terns Stock
| 0.68 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.65 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.64 | LLY | Eli Lilly Sell-off Trend | PairCorr |
| 0.78 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Terns Stock
Terns Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Amy MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Israel Wall Street (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Israel Wall Street, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTerns Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Terns Pharmaceuticals' financial leverage. It provides some insight into what part of Terns Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Terns Pharmaceuticals (TERN) is traded on NASDAQ Exchange in USA. It is located in 1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404 and employs 66 people. Terns Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 499.44 M. Terns Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 84.94 M outstanding shares of which 4.54 M shares are at this time shorted by private and institutional investors with about 3.16 trading days to cover.
Terns Pharmaceuticals currently holds about 139.81 M in cash with (67.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.51.
Check Terns Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationTerns Pharmaceuticals shows a total of 84.94 Million outstanding shares. The majority of Terns Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Terns Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Terns Pharmaceuticals. Please pay attention to any change in the institutional holdings of Terns Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Terns Ownership Details
Terns Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Exoduspoint Capital Management, Lp | 2024-09-30 | 1.6 M | |
| Superstring Capital Management Lp | 2024-09-30 | 1.3 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.2 M | |
| State Street Corp | 2024-06-30 | 1.2 M | |
| Fmr Inc | 2024-09-30 | 1.2 M | |
| Great Point Partners Llc | 2024-06-30 | 1.1 M | |
| Millennium Management Llc | 2024-06-30 | 1.1 M | |
| Driehaus Capital Management Llc | 2024-06-30 | 1.1 M | |
| Bellevue Group Ag | 2024-09-30 | 1 M | |
| Orbimed Advisors, Llc | 2024-06-30 | 7.6 M | |
| Vivo Capital, Llc | 2024-09-30 | 6.9 M |
Terns Pharmaceuticals Historical Income Statement
Terns Stock Against Markets
Terns Pharmaceuticals Corporate Management
| David Strauss | VP Controller | Profile | |
| Pamela Danagher | Senior Assurance | Profile | |
| Debra Sieminski | Senior Affairs | Profile | |
| Jeffrey Jasper | Senior Research | Profile | |
| JD Esq | Chief Officer | Profile | |
| Senthil Sundaram | CEO Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 0.035 | Return On Assets (0.19) | Return On Equity (0.28) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.